Baricitinib as the first systemic treatment for severe alopecia areata

References

• Darwin E, Hirt P, Fertig R, et al. Review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichology. 2018;10(2):51–60.
   PubMedGoogle Scholar
• Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1–12. DOI:10.1016/j.jaad.2017.04.1141
   PubMed Web of Science ®Google Scholar
• Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;8:397.
   PubMed Web of Science ®Google Scholar
• Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70(7):628–633.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Anderson S, Edson-Heredia E, et al. Comorbidities of alopecia areata: a population-based cohort study. Clin Exp Dermatol. 2021;46(4):651–665.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee H, Lee CH, et al. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(2):466–77.e16.
   PubMed Web of Science ®Google Scholar
• Huang KP, Mullangi S, Guo Y, et al. Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013;149(7):789–794.
   PubMed Web of Science ®Google Scholar
• Sellami R, Masmoudi J, Ouali U, et al. The relationship between alopecia areata and alexithymia, anxiety and depression: a case-control study. Indian J Dermatol. 2014;59(4):421. DOI:10.4103/0019-5154.135525
   PubMed Web of Science ®Google Scholar
• Ruiz-Doblado S, Carrizosa A, García-Hernández MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol. 2003;42(6):434–437.
   PubMed Web of Science ®Google Scholar
• Colón EA, Popkin MK, Callies AL, et al. Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry. 1991;32(3):245–251.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Roberts J, Sperling L, et al. Objective outcome measures: collecting meaningful data on alopecia areata. J Am Acad Dermatol. 2018;79(3):470. DOI:10.1016/j.jaad.2017.10.048
   PubMed Web of Science ®Google Scholar
• King BA, Mesinkovska NA, Craiglow B, et al. Development of the alopecia areata scale for clinical use: results of an academic–industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359–364. DOI:10.1016/j.jaad.2021.08.043
   PubMed Web of Science ®Google Scholar
• Wyrwich KW, Kitchen H, Knight S, et al. Development Of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. Am J Clin Dermatol. 2020;21(5):725–732. DOI:10.1007/s40257-020-00545-9
   PubMed Web of Science ®Google Scholar
• Guo H, Cheng Y, Shapiro J, et al. The role of lymphocytes in the development and treatment of alopecia areata. Expert Rev Clin Immunol. 2015;11(12):1335.
   PubMed Web of Science ®Google Scholar
• Triyangkulsri K, Suchonwanit P. Role of Janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. 2018;12:2323.
   PubMed Web of Science ®Google Scholar
• Dillon KAL. A comprehensive literature review of jak inhibitors in treatment of alopecia areata. Clin Cosmet Investig Dermatol. 2021;14:691–714.
   PubMed Web of Science ®Google Scholar
• Paus R, Bertolini M The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. Journal of Investigative Dermatology Symposium Proceedings. 2013;16:p. S25–27
   Google Scholar
• Rajabi F, Drake LA, Senna MM, et al. Alopecia areata: a review of disease pathogenesis. Br J Dermatol. 2018;179:1033–1048.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, et al. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521.
   PubMed Web of Science ®Google Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049. DOI:10.1038/nm.3645
   PubMed Web of Science ®Google Scholar
• Zhou C, Li X, Wang C, et al. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clinical Reviews in Allergy & Immunology. 2021;61:403–423.
   PubMed Web of Science ®Google Scholar
• Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15–24. DOI:10.1016/j.jaad.2017.04.1142
   PubMed Web of Science ®Google Scholar
• Yee BE, Tong Y, Goldenberg A, et al. Efficacy of different concentrations of intralesional triamcinolone acetonide for alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(4):1018–1021.
   PubMed Web of Science ®Google Scholar
• Tosti A, Iorizzo M, Botta GL, et al. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol. 2006;20:1243–1247.
   PubMed Web of Science ®Google Scholar
• Freire PCB, Riera R, Martimbianco ALC, et al. Minoxidil for patchy alopecia areata: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33:1792–1799.
   PubMed Web of Science ®Google Scholar
• Trüeb RM, Dias MFRG. Alopecia areata: a comprehensive review of pathogenesis and management. Clin Rev Allergy Immunol. 2018;54(1):68–87.
   PubMed Web of Science ®Google Scholar
• Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol. 2017;76(4):736–744.
   PubMed Web of Science ®Google Scholar
• Crispin MK, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1. DOI:10.1172/jci.insight.89776
   Web of Science ®Google Scholar
• Wang Y, Liu T, Li S, et al. Efficacy and safety of baricitinib in patients with refractory alopecia areata. Dermatol Ther. Published online Oct 18, 2022;35(12). DOI:10.1111/dth.15845
   Web of Science ®Google Scholar
• Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33:850–856.
   PubMed Web of Science ®Google Scholar
• Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol. 2018;79(3):535–544.
   PubMed Web of Science ®Google Scholar
• Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol. 2018;78(2):403–4.e1.
   PubMed Web of Science ®Google Scholar
• Ismail FF, Sinclair R. JAK inhibition in the treatment of alopecia areata – a promising new dawn? Expert Rev Clin Pharmacol. 2020;13(1):43–51.
   PubMed Web of Science ®Google Scholar
• King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847–853. DOI:10.1016/j.jaad.2021.05.050
   PubMed Web of Science ®Google Scholar
• King B, Mesinkovska N, Mirmirani P, et al. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata. J Am Acad Dermatol. 2022;87(2):306–313. DOI:10.1016/j.jaad.2022.03.045
   PubMed Web of Science ®Google Scholar
• King B, Ohyama M, Kwon O, et al. Two Phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687–1699. DOI:10.1056/NEJMoa2110343
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Pavel AB, Diaz A, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022;149(4):1318–1328. DOI:10.1016/j.jaci.2021.10.036
   PubMed Web of Science ®Google Scholar
• Assadiasl S, Fatahi Y, Mosharmovahed B, et al. Baricitinib: from rheumatoid arthritis to COVID-19. J Clin Pharmacol. 2021;61(10):1274–1285.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298–5307. DOI:10.4049/jimmunol.0902819
   PubMed Web of Science ®Google Scholar
• Mogul A, Corsi K, McAuliffe LB. The Second FDA-Approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother. 2019;53(9):947–953.
   PubMed Web of Science ®Google Scholar
• Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54(12):1354–1361. DOI:10.1002/jcph.354
   PubMed Web of Science ®Google Scholar
• Olumiant (baricitinib) [Package insert]. Indianapolis IN: Eli Lilly and Company. 2022.
   Google Scholar
• Markham A. Baricitinib: first global approval. Drugs. 2017;77:697–704.
   PubMed Web of Science ®Google Scholar
• Payne C, Zhang X, Shahri N, et al. Ab0492 evaluation of potential drug-drug interactions with baricitinib. Ann Rheum Dis. 2015;74(Suppl 2):1063.
   Google Scholar
• Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with The JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2:351–355.
   PubMed Web of Science ®Google Scholar
• Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. JAAD Case Rep. 2019;5(10):892–894.
   PubMedGoogle Scholar
• Uchida H, Kamata M, Nagata M, et al. Baricitinib improved alopecia areata concomitant with atopic dermatitis: a case report. J Dermatol. 2021;48(9):e472–3. DOI:10.1111/1346-8138.16024
   PubMed Web of Science ®Google Scholar
• Bieber T, Feist E, Irvine AD, et al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv Ther. 2022;39(11):4910–4960. DOI:10.1007/s12325-022-02281-4
   PubMed Web of Science ®Google Scholar